Efficacy of Cellex in patients with mild cognitive impairment
https://doi.org/10.17650/2222-8721-2016-6-3-17-23
Abstract
Background. Cognitive disorders may often lead to professional invalidisation and increasing dependence on the external assistance in every day life. Identification of patients with preserved intellectual status and social adaptation but with mild cognitive impairment (MCI) is considered to be an effective measure. MCI detection and timely initiation of treatment in most patients is essential to delay the onset of severe dementia.
Objective. Investigating influence of Cellex in patients with chronic cerebral ischemia and MCI.
Materials and methods. As a part of non-interventional observational comparative study we evaluated the results of Cellex administration in 90 patients with MCI. Patients were divided into 2 groups. Patients from both groups received 1 course of 10 subcutaneous injections of Cellex drug at the dose of 1 mL, and patients from group 2 received two identical courses with an interval of two months. The survey, which included psychometric testing by using special questionnaires (Mini-Mental State Examination, “Frontal Assessment Battery” and “Clock Drawing” tests, Schulte test) was performed before treatment, and at months 1 and 2 after its completion.
Results. Neuropsychological examination revealed improvement in the patients state, more pronounced after the 2nd course of therapy.
Discussion. Our results provide a basis for using Cellex in patients with chronic cerebral ischemia and MCI, allowing to proceede with further studies on the optimal dosage of that drug.
About the Authors
B. A. Abusueva
Dagestan State Medical Academy, Ministry of Health of Russia
Russian Federation
Russian Federation
M. A. Evzel’man
I.S. Turgenev Oryol State University, Medical Institute
Russian Federation
Russian Federation
P. R. Kamchatnov
N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia
Russian Federation
Russian Federation
Kh. Yu. Umarova
Medical Faculty, Chechen State University
Russian Federation
Russian Federation
References
1. Waldemar G., Dubois B., Emre M. Alz heimer’s disease and other disorders associated with dementia. In book: European handbook of neurological management. Eds.: R. Hughes, M. Brainin, N. Gilhus. Oxford: Blackwell Publishing, 2006. 640 p.
2. Захаров В.В., Вахнина Н.В. Когнитивные нарушения при цереброваскулярных заболеваниях. Неврология и психиатрия 2014;(1):36–43. [Zakharov V.V., Vakhnina N.V. Cognitive impairment in cerebrovascular diseases. Nevrologiya i psikhiatriya = Neurology and Psychiatry 2014;(1):36–43. (In Russ.)].
3. Gauthier S., Touchon J. Subclassification of mild cognitive impairment in research and clinical practice. In book: Alzheimer’s disease and related disorders. Eds.: S. Gauthier, P. Scheltens, J. Cummings. London, UK: Martin Dunitz, 2004. Pp. 61–69.
4. Левин О.С. Алгоритмы диагностики и лечения деменции. М.: МЕДпресс-информ, 2012. [Levin О.S. Аlgorithms of dementia diagnostics and treatment. Мoscow: МЕDpress-infоrm, 2012. (In Russ.)].
5. Гусев Е.И., Боголепова Н.Н. Когнитивные нарушения при цереброваскулярных заболеваниях. М.: МЕДпресс-информ, 2014. [Gusev Е.I., Bogolepovа N.N. Cognitive impairment in cerebrovascular disorders. Мoscow: МЕDpress-infоrm, 2014. (In Russ.)].
6. Гусев Е.И., Камчатнов П.Р. Пластичность головного мозга в норме и патологии. Журнал неврологии и пси хиатрии им. С.С. Корсакова 2004;(2):73–80. PMID: 15071851. [Gusev Е.I., Kamchatnov P.R. Normal and pathologic brain plasticity. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry 2004;(2):73–80. PMID: 15071851. (In Russ.)].
7. Ali M.R., Abo-Youssef A.M., Messiha B.A., Khattab M.M. Tempol and perindopril protect against lipopolysaccharide-induced cognition impairment and amyloidogenesis by modulating brain-derived neurotropic factor, neuroinflammation and oxidonitrosative stress. Naunyn Schmiedebergs Arch Pharmacol 2016;389(6):637–56. DOI: 10.1007/s00210-016-1234-6. PMID: 27026404.
8. Anaeigoudari A., Soukhtanloo M., Shafei M. et al. Neuronal nitric oxide synthase has a role in the detrimental effects of lipopolysaccharide on spatial memory and synapticplasticity in rats. Pharmacol Rep 2016;68(2):243–9. DOI: 10.1016/j.pharep.2015.09.004.
9. Гомазков О.А. Нейротрофические факторы мозга. М.: НИИ биомедицинской химии РАМН, 2004. 311 с. [Gomazkov О.А. Neurotrophic brain factors. Мoscow: NII biomeditsinskoy khimii RAMN, 2004. 311 p. (In Russ.)].
10. Дурнев А.Д. Исследование мутагенности и потенциальной канцерогенности препарата «белково-пептидный комплекс» (БПК) в краткосрочных тестах. М.: НИИ фармакологии им. В.В. Закусова РАМН, 2011. [Durnev А.D. Studies of mutagenecity and of potential cancerogenicity of the “protein-peptide complex substance” (PPCS) in short term tests. Моscow: NII farmakologii im. V.V. Zakusova RAMN, 2011. (In Russ.)].
11. Романова Г.А., Шакова Ф.М., Барсков И.В. и др. Влияние целлекса на функциональные и морфологические изменения при экспериментальной фокальной ишемии префронтальной коры головного мозга. Журнал неврологии и психиатрии им. С.С. Корсакова 2010;110(9):52–6. PMID: 21462442. [Romanova G.А., Shakovа F.М., Barskov I.V. et al. Cellex influence on functional and morphologic changes at the experimental focal ischemia of the medial prefrontal cortex. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry 2010;110(9): 52–6. PMID: 21462442. (In Russ.)].
12. Пизова Н.В., Соколов М.А., Измайлов И.А. Целлекс в лечении больных с острым нарушением мозгового кровообращения: результаты российского многоцентрового сравнительного откры того клинического исследования. Журнал неврологии и психиатрии им. С.С. Корсакова 2014;114(5):22–6. PMID: 24988954. [Pizovа N.V., Sokolov М.А., Izmaylov I.А. Cellex in the treatment of patients with acute cerebrovascular accident: results of Russian multicenter comparative open clinical studies. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry 2014;114(5): 22–6. PMID: 24988954. (In Russ.)].
13. Коваленко А.В., Сафронова М.Н. Влияние целлекса на восстановление когнитивных и речевых нарушений в остром периоде инсульта. Журнал неврологии и психиатрии им. С.С. Корсакова 2015;115(1):40–4. PMID: 25909788. [Kovalenko А.V., Safronovа М.N. Cellex influence on the restoration of cognitive and speech deteriorations in the acute period of stroke. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova =S.S. Korsakov Journal of Neurology and Psychiatry 2015;115(1): 40–4. PMID: 25909788. (In Russ.)].
14. Камчатнов П.Р., Чугунов А.В., Умарова Х.Я. Метаболическая терапия ишемического инсульта. Фарматека 2015; 302(9):20–7. [Kamchatnov P.R., Chugunov А.V., Umarova Kh.Ya. Меtabolic therapy of the ischemic stroke. Farmateka =Pharmateca 2015;302(9):20–7. (In Russ.)].
15. Бельская Г.Н., Крылова Л.Г., Соко лов М.А., Измайлов И.А. Возможности коррекции речевых расстройств в остром периоде ишемического инсульта с помощью нейропротективной терапии. Журнал неврологии и психиатрии им. С.С. Кор сакова 2015;115(9):60–3. DOI: 10.17116/jnevro20151159260-63. [Bel’skaya G.N., Krylovа L.G., Sokolov М.А., Izmaylov I.А. Possibilities for the correction of speech disorders with the neuroprotective therapy in stroke. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry 2015;115(9):60–3. DOI: 10.17116/jnevro20151159260-63. (In Russ.)].
16. Левин О.С. Алгоритмы диагностики и лечение деменции. 5-е издание. М.: МЕД-пресс-информ, 2012. [Levin О.S. Аlrorithms of dementia diagnostics and treatment. 5th ed. Мoscow: МЕDpress-inform, 2012. (In Russ.)].
Review
For citations:
Abusueva B.A., Evzel’man M.A., Kamchatnov P.R., Umarova Kh.Yu. Efficacy of Cellex in patients with mild cognitive impairment. Neuromuscular Diseases. 2016;6(3):17-23. (In Russ.) https://doi.org/10.17650/2222-8721-2016-6-3-17-23
Views:
1558
Email this article 